Figure 1From: Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients Baseline and follow-up measures. (a) AI therapy, FDG PET SUV. (b) T therapy, FDG PET SUV. (c) AI therapy, Ki-67% staining. (d) T therapy, Ki-67% staining.Back to article page